Floatz logo

(+)-VINCRISTINE

DPD Deficiency

UNICANCERSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the DPD Deficiency cohort.

Asset / SponsorPhaseRating
Nivolumab
UNICANCER
Phase 2CCC
Eloxatin
UNICANCER
Phase 2CCC
Trifluridine
UNICANCER
Phase 2CCC
PANITUMUMAB
UNICANCER
Phase 2CCC
Irinotecan
UNICANCER
Phase 2CCC
TRASTUZUMAB
UNICANCER
Phase 2CCC

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →